For PAX1 methylation studies specifically, multi-center trials with diverse populations(different regions and ethnic groups were included) are indeed needed to establish broader clinical utility, as suggested in the literature on cancer biomarkers and molecular diagnostics. The gene discussed is PAX1; the disease is cancer.